Hypertrophic cardiomyopathy: a review.

Hypertrophic cardiomyopathy (HCM) is a relatively common disorder that anesthesiologists encounter among patients in the perioperative period. Fifty years ago, HCM was thought to be an obscure disease. Today, however, our understanding and ability to diagnose patients with HCM have improved dramatically. Patients with HCM have genotypic and phenotypic variability. Indeed, a subgroup of these patients exhibits the HCM genotype but not the phenotype (left ventricular hypertrophy). There are a number of treatment modalities for these patients, including pharmacotherapy to control symptoms, implantable cardiac defibrillators to manage malignant arrhythmias, and surgical myectomy and septal ablation to decrease the left ventricular outflow obstruction. Accurate diagnosis is vital for the perioperative management of these patients. Diagnosis is most often made using echocardiographic assessment of left ventricular hypertrophy, left ventricular outflow tract gradients, systolic and diastolic function, and mitral valve anatomy and function. Cardiac magnetic resonance imaging also has a diagnostic role by determining the extent and location of left ventricular hypertrophy and the anatomic abnormalities of the mitral valve and papillary muscles. In this review on hypertrophic cardiomyopathy for the noncardiac anesthesiologist, we discuss the clinical presentation and genetic mutations associated with HCM, the critical role of echocardiography in the diagnosis and the assessment of surgical interventions, and the perioperative management of patients with HCM undergoing noncardiac surgery and management of the parturient with HCM.

Update on ventricular assist devices.

PURPOSE OF REVIEW: Over the past two decades, medicine has seen a robust increase in the use of ventricular assist devices. The purpose of this review is to update the information concerning these devices, their advantages and disadvantages as well as their complications. This is essential, as the demand for these devices is increasing due to the increasing number of patients with end-stage heart failure and limited number of donor hearts available for transplantation. RECENT FINDINGS: First-generation devices consisted of large, cumbersome consoles requiring patient immobilization and often times hospitalization in an ICU setting. Second-generation models focused on patient mobility and discharge from hospital with an improvement in infection rates as well as 1 and 2-year survival rates. Designs for newer devices are focusing on full implantation without percutaneous lines, axial flow mechanisms and patient comfort. Additionally, total artificial hearts are being designed for the treatment of biventricular failure. The indications for ventricular assist devices are also being expanded to include destination therapy and alternatives to cardiac transplantation, as the supply of organs continues to be limiting. SUMMARY: This paper reviews the characteristics, outcomes and design of ventricular assist devices.

Renal failure in patients with left ventricular assist devices.

Implantable left ventricular assist devices (LVADs) are increasingly being used as a bridge to transplantation or as destination therapy in patients with end stage heart failure refractory to conventional medical therapy. A significant number of these patients have associated renal dysfunction before LVAD implantation, which may improve after LVAD placement due to enhanced perfusion. Other patients develop AKI after implantation. LVAD recipients who develop AKI requiring renal replacement therapy in the hospital or who ultimately require long-term outpatient hemodialysis therapy present management challenges with respect to hemodynamics, volume, and dialysis access. This review discusses the mechanics of a continuous-flow LVAD (the HeartMate II), the effects of continuous blood flow on the kidney, renal outcomes of patients after LVAD implantation, dialysis modality selection, vascular access, hemodynamic monitoring during the dialytic procedure, and other issues relevant to caring for these patients.

Intraoperative transesophageal echocardiography and ventricular assist device insertion.

A decade after cardiac surgery was established, transesophageal echocardiography (TEE) was developed and used to evaluate perioperative cardiac performance. It has become an invaluable tool to provide real-time information in the cardiac operating room. TEE provides practical and useful information prior to insertion as well as after placement of the device. Additionally, during episodes of device malfunction or hemodynamic instability, TEE can be extremely useful in defining the etiology of the problem. As ventricular assist devices (VADs) have undergone evolution in design and as more VADs are being implanted, the development of specific indications for TEE use during device placement is a relevant issue. Formal guidelines for use of TEE during VAD insertion are yet to be adopted or implemented, but for now TEE remains an essential tool for managing this patient population.

Renal injury is associated with operative mortality after cardiac surgery for women and men.

OBJECTIVES: The purpose of this study was to determine whether acute renal injury develops more frequently in women than in men after cardiac surgery and whether this complication is associated with operative mortality in women. METHODS: Prospectively collected data were evaluated from 9461 patients undergoing coronary artery bypass graft surgery, cardiac valve surgery, or both (3080 women) and not receiving preoperative dialysis. The glomerular filtration rate was estimated by using the Modification of Diet in Renal Disease equations with the last plasma creatinine level before surgical intervention (baseline) and the highest level of the first postoperative week. The primary renal injury outcome was the composite end point of renal injury according to RIFLE criteria (estimated glomerular filtration rate decrease >50% from baseline value) or failure. RESULTS: Thirty-day operative mortality and renal injury were more common in women than in men (5.9% vs 2.8%, P = .01; 5.1% vs 3.6%, P < .001, respectively). Nonetheless, patient sex was not independently associated with risk for renal injury when the baseline estimated glomerular filtration rate was included in multivariate modeling. Perioperative complications, intensive care unit length of stay, and mortality were more frequent for patients with than without renal injury (women, 20.6% vs 3.2%, P < .0001; men, 18.3% vs 2.2%, P < .001). Renal injury was independently associated with 30-day mortality for women (odds ratio, 3.96; 95% confidence interval, 1.86-8.44; P < .0001) and men (odds ratio, 4.05; 95% confidence interval, 2.19-7.48; P < .0001). CONCLUSIONS: Postoperative renal injury is independently associated with 30-day mortality regardless of patient sex. Higher rates of renal injury in women compared with men might be explained in part by a higher prevalence of low estimated glomerular filtration rate before surgical intervention.

The impact of obesity on outcomes after critical illness: a meta-analysis.

PURPOSE: To assess whether obesity is associated with mortality or other adverse intensive care unit (ICU) and post-ICU outcomes. METHODS: A meta-analysis of studies from PubMed and EMBASE databases. RESULTS: Twenty-two studies (n = 88,051 patients) were included. Pooled analysis demonstrated no difference in ICU mortality, but lower hospital mortality for obese and morbidly obese subjects (RR 0.76; 95% CI 0.59, 0.92; RR 0.83; 95% CI 0.66, 1.04, respectively) versus normal weight subjects. There was no association between obesity and duration of mechanical ventilation or ICU stay. Morbidly obese versus normal weight patients had longer hospitalizations. No study reported physical function, mental health, or quality of life outcomes after discharge. CONCLUSIONS: Obesity is not associated with increased risk for ICU mortality, but may be associated with lower hospital mortality. There is a critical lack of research on how obesity may affect complications of critical illness and patient long-term outcomes.